Topics include: Clinical Predictors of Outcome in MPNs; Molecular pathogenesis of MPNs; Disordered signaling in MPNs; Role of TET2/ASXL1 in MPN Pathogenesis; Pathogenesis and treatment of systemic mastocytosis; Role of additional novel therapies in MPNs; Role of novel mutations in MPN pathogenesis and outcome; Role of JAK inhibitors in MPN treatment; Animal Models of MPNs; and Role of Germline Genetic Factors in MPN Pathogenesis.
| Preface |
|
xi | |
|
|
|
Role of Additional Novel Therapies in Myeloproliferative Neoplasms |
|
|
959 | (22) |
|
|
|
|
|
|
|
|
|
Acquired Uniparental Disomy in Myeloproliferative Neoplasms |
|
|
981 | (12) |
|
|
|
|
|
Genotype-Phenotype Interactions in the Myeloproliferative Neoplasms |
|
|
993 | (24) |
|
|
|
|
|
Disordered Signaling in Myeloproliferative Neoplasms |
|
|
1017 | (20) |
|
|
|
|
|
Role of Germline Genetic Factors in MPN Pathogenesis |
|
|
1037 | (16) |
|
|
|
|
|
Role of TET2 and ASXL1 Mutations in the Pathogenesis of Myeloproliferative Neoplasms |
|
|
1053 | (12) |
|
|
|
|
|
|
|
Myeloproliferative Neoplasm Animal Models |
|
|
1065 | (18) |
|
|
|
|
|
|
|
|
|
Therapy with JAK2 Inhibitors for Myeloproliferative Neoplasms |
|
|
1083 | (18) |
|
|
|
|
|
Clinical Predictors of Outcome in MPN |
|
|
1101 | (16) |
|
|
|
|
|
|
|
|
|
|
|
Systemic Mastocytosis: Disease Overview, Pathogenesis, and Treatment |
|
|
1117 | (12) |
|
|
| Index |
|
1129 | |
Human Oncology and Pathogenesis Program. Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Daugiau apie elektronines knygas